Risperidone-induced hyperamylasemia, hyperlipasemia, and neuroleptic malignant syndrome: a case report

J Clin Psychopharmacol. 2009 Aug;29(4):391-2. doi: 10.1097/JCP.0b013e3181ad2064.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antipsychotic Agents / administration & dosage
  • Antipsychotic Agents / adverse effects*
  • Female
  • Humans
  • Hyperamylasemia / chemically induced*
  • Hyperamylasemia / diagnosis
  • Hyperamylasemia / therapy
  • Injections, Intramuscular
  • Intubation, Gastrointestinal
  • Lipase / blood*
  • Lorazepam / administration & dosage
  • Middle Aged
  • Neuroleptic Malignant Syndrome / diagnosis
  • Neuroleptic Malignant Syndrome / etiology*
  • Neuroleptic Malignant Syndrome / therapy
  • Pancreatitis / chemically induced*
  • Pancreatitis / diagnosis
  • Pancreatitis / therapy
  • Risperidone / adverse effects*
  • Schizophrenia, Disorganized / drug therapy*
  • Treatment Outcome
  • Urinary Catheterization

Substances

  • Antipsychotic Agents
  • Lipase
  • Risperidone
  • Lorazepam